Affimed FY2025 EPS Estimate Increased by Cantor Fitzgerald

Affimed (NASDAQ:AFMD) – Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for shares of Affimed in a report issued on Thursday, May 15th. Cantor Fitzgerald analyst L. Watsek now expects that the biopharmaceutical company will post earnings per share of ($0.86) for the year, up from their previous forecast of ($2.07). Cantor Fitzgerald has a “Hold” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.19) per share.

Several other equities research analysts also recently issued reports on AFMD. Leerink Partners reaffirmed a “market perform” rating and set a $0.39 price target (down previously from $5.00) on shares of Affimed in a report on Tuesday, May 13th. Wells Fargo & Company reiterated an “equal weight” rating and set a $0.10 price objective (down previously from $11.00) on shares of Affimed in a research report on Tuesday, May 13th. HC Wainwright cut Affimed from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. StockNews.com initiated coverage on Affimed in a research report on Sunday, May 11th. They set a “sell” rating on the stock. Finally, Leerink Partnrs cut Affimed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.90.

Affimed Trading Up 227.8%

Shares of Affimed stock opened at $0.28 on Monday. The business has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $1.39. Affimed has a 1 year low of $0.07 and a 1 year high of $8.95. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Affimed stock. Northern Trust Corp purchased a new position in Affimed (NASDAQ:AFMD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 183,118 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Northern Trust Corp owned 1.14% of Affimed as of its most recent filing with the Securities and Exchange Commission (SEC). 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.